Instadose Pharma (Instadose Pharma) Net Change in Cash : $-0.03 Mil (TTM As of Feb. 2022)

View and export this data going back to 2019. Start your Free Trial

What is Instadose Pharma Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Instadose Pharma's Net Change in Cash for the three months ended in Feb. 2022 was $-0.01 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Feb. 2022 was $-0.03 Mil.

Instadose Pharma Net Change in Cash Historical Data

The historical data trend for Instadose Pharma's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Instadose Pharma Net Change in Cash Chart

Instadose Pharma Annual Data

Trend

Nov16

Nov17

Nov18

Nov19

Nov20

Nov21

Net Change in Cash

Get a 7-Day Free Trial

-0.01

Instadose Pharma Quarterly Data
	May17	Aug17	Nov17	Feb18	May18	Aug18	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22
Net Change in Cash	Get a 7-Day Free Trial															0.02	-0.02	-	-	-0.01

Instadose Pharma Net Change in Cash Calculation

Instadose Pharma's Net Change in Cash for the fiscal year that ended in Nov. 2021 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	0	+	0	+	0	+	0
	=	0.00

Instadose Pharma's Net Change in Cash for the quarter that ended in Feb. 2022

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= 0.126 + 0.004 + -0.139 + 0

= -0.01

Net Change in Cash for the trailing twelve months (TTM) ended in Feb. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.03 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Instadose Pharma Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Instadose Pharma's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Instadose Pharma (Instadose Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Instadose Pharma Corp (OTCPK:INSD) » Definitions » Net Change in Cash

Comparable Companies

LZB SNBR IRBT AMWD TILE ETD COOK LOVE PRPL WEBR SZSE:000333 SHSE:600690 SZSE:000651 SHSE:603833 WHR FBHS MHK SHSE:603486 SZSE:002032 SHSE:605117

Traded in Other Exchanges

N/A

Address

5500 North Service Road, Suite 301, Burlington, ON, CAN, L7L 6W6

Website

https://www.instadosepharma.com

Instadose Pharma Corp, formerly Mikrocoze Inc is seeking to create a global distribution platform for medicinal cannabis and cannabinoid oil. The company endeavors to utilize the Global Distribution Platform to open the commercial gateway to a new wholesale marketplace along with providing pharmaceutical industry companies with large, sustainable, consistent, diverse, and low?cost supplies of high?quality medicinal cannabis and cannabinoid oil for use in bulk as an active pharmaceutical ingredient.

Instadose Pharma (Instadose Pharma) Headlines

From GuruFocus

Investor Notice: Feb 28th Deadline for certain Investors in Instadose Pharma Corp. shares announced by Shareholders Foundation
By PRNewswire PRNewswire • 02-16-2022

INSD ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of February 28, 2022 in the Class Action Filed on Behalf of Instadose Pharma Corp. f/k/a Mikrocoze, Inc. Shareholders
By PRNewswire PRNewswire • 02-15-2022

INSD LAWSUIT ALERT: Levi & Korsinsky Notifies Instadose Pharma Corp. f/k/a Mikrocoze, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
By PRNewswire PRNewswire • 02-17-2022

INSD SHAREHOLDER ALERT: Jakubowitz Law Reminds Instadose Shareholders of a Lead Plaintiff Deadline of February 28, 2022
By PRNewswire PRNewswire • 02-18-2022

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Instadose Investors of a Lead Plaintiff Deadline of February 28, 2022
By PRNewswire PRNewswire • 02-22-2022

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Instadose Investors of a Lead Plaintiff Deadline of February 28, 2022
By PRNewswire PRNewswire • 02-14-2022

DEADLINE ALERT for INSD, MMAT, BHG, TLIS: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
By GuruFocusNews GuruFocusNews • 02-23-2022

INSD ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of February 28, 2022 in the Class Action Filed on Behalf of Instadose Pharma Corp. f/k/a Mikrocoze, Inc. Shareholders
By PRNewswire PRNewswire • 02-08-2022

ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Instadose Pharma Corp. f/k/a Mikrocoze, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action � INSD, MZKR
By GuruFocusNews GuruFocusNews • 02-11-2022

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Instadose Pharma Corp. f/k/a Mikrocoze, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 28, 2022 - (OTC Other: INSD)
By PRNewswire PRNewswire • 02-09-2022